Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-07293893 on skeletal muscle biomarkers in healthy adults
NCT06413693Phase 1Completed
- Sponsor
- Pfizer
- Start
- May 2024
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PF-07293893 in heart failure (HF) (2 cohorts), sponsored by Pfizer. Primary endpoint: Change from baseline of skeletal muscle pACC/tACC ratio. Started May 2024; status: completed.
02
Drugs
PF-07293893
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT06413693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06413693.